Table 1.
Biomarker/target | Approved drug(s) | Year of FDA approval |
---|---|---|
dMMR | Pembrolizumab | 2017 |
Dostarlimab | 2022 | |
MSI-H | Pembrolizumab | 2017 |
TMB-High | Pembrolizumab | 2020 |
BRAF V600E | Dabrafenib + Trametinib | 2022 |
RET fusions | Selpercatinib | 2022 |
NTRK fusions | Larotrectinib | 2018 |
Entrectinib | 2019 |